(Q39557682)

13 September 2017

Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies (English)

1 reference

13 September 2017

1 reference

Marco Muda

1

1 reference

13 September 2017

Alec W Gross

2

1 reference

13 September 2017

Jessica P Dawson

3

1 reference

13 September 2017

Chaomei He

4

1 reference

13 September 2017

Emmi Kurosawa

5

1 reference

13 September 2017

Rene Schweickhardt

6

1 reference

13 September 2017

Melanie Dugas

7

1 reference

13 September 2017

Maria Soloviev

8

1 reference

13 September 2017

Anna Bernhardt

9

1 reference

13 September 2017

David Fischer

10

1 reference

13 September 2017

John S Wesolowski

11

1 reference

13 September 2017

Christie Kelton

12

1 reference

13 September 2017

Berend Neuteboom

13

1 reference

13 September 2017

Bjoern Hock

14

1 reference

13 September 2017

1 May 2011

1 reference

Protein Engineering Design and Selection

13 September 2017

1 reference

13 September 2017

24

1 reference

13 September 2017

5

1 reference

13 September 2017

447-454

1 reference

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

13 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Strategies and challenges for the next generation of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Potent antibody therapeutics by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Clinical genetics for the pulmonologist: introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

A broad range of Fab stabilities within a host of therapeutic IgGs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

A revival of bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

When binding is enough: nonactivating antibody formats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

An efficient route to human bispecific IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Bispecific antibodies for cancer immunotherapy: Current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ123

21 January 2018

Identifiers

DOI

10.1093/PROTEIN/GZQ123

1 reference

13 September 2017

1 reference